---
figid: PMC8344275__jitc-2021-002899f01
figtitle: Deregulation of HLA-I in cancer and its central importance for immunotherapy
organisms:
- Homo sapiens
- Mus musculus
- Equus caballus
- NA
organisms_ner:
- Mus musculus
- Equus caballus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8344275
filename: jitc-2021-002899f01.jpg
figlink: /pmc/articles/PMC8344275/figure/F1/
number: F1
caption: Possible deficiencies in antigen presenting machinery. (1) Acquired mutations,
  transcriptional or post-transcriptional regulations in HLA or antigen presentation
  machinery (APM) genes or epigenetic modifications in their promoter regions. (2,
  3) Defects in type-I or type-II interferon pathways, which are direct stimulators
  of HLA-I expression. (4) Aberrant activation of PI3K-Akt oncogenic pathway interferes
  with phosphorylation of STAT1 and hinders interferon mediated HLA-I expression.
  (5) Oncogenic BRAF mutation can drive internalization and endosomal degradation
  of surface HLA-I antigens. (6) Autophagy cargo receptor NBR1 protein can bind to
  HLA-I leads to autophagy-mediated degradation. (7) Defects in the proteasome components
  (LMP2, LMP9 or MECL-1, etc). (8) Defects in the peptide transport or ER peptide
  loading complex (TAP1/TAP2, ERp57, calnexin, calreticulin). (9) Downregulation of
  light chain β2M can lead to complete absence of HLA-I. (10) Microenvironmental conditions
  such as glucose deprivation, hypoxia, acidosis or excessive IL-10, TGF-β levels
  can also drive loss of HLA. β2M, β−2-microglobulin; ER, endoplasmic reticulum; HLA,
  human leucocyte antigen; IFNAR1, interferon alpha and beta receptor 1; IL-10, interleukin
  10; ISRE, interferon stimulated response element; TAP1, transporter associated with
  antigen processing 1; TGF-β, transforming growth factor-β.
papertitle: Deregulation of HLA-I in cancer and its central importance for immunotherapy.
reftext: Ahmet Hazini, et al. J Immunother Cancer. 2021;9(8):e002899.
year: '2021'
doi: 10.1136/jitc-2021-002899
journal_title: Journal for Immunotherapy of Cancer
journal_nlm_ta: J Immunother Cancer
publisher_name: BMJ Publishing Group
keywords: immunity | cellular | immunotherapy
automl_pathway: 0.9574307
figid_alias: PMC8344275__F1
figtype: Figure
redirect_from: /figures/PMC8344275__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8344275__jitc-2021-002899f01.html
  '@type': Dataset
  description: Possible deficiencies in antigen presenting machinery. (1) Acquired
    mutations, transcriptional or post-transcriptional regulations in HLA or antigen
    presentation machinery (APM) genes or epigenetic modifications in their promoter
    regions. (2, 3) Defects in type-I or type-II interferon pathways, which are direct
    stimulators of HLA-I expression. (4) Aberrant activation of PI3K-Akt oncogenic
    pathway interferes with phosphorylation of STAT1 and hinders interferon mediated
    HLA-I expression. (5) Oncogenic BRAF mutation can drive internalization and endosomal
    degradation of surface HLA-I antigens. (6) Autophagy cargo receptor NBR1 protein
    can bind to HLA-I leads to autophagy-mediated degradation. (7) Defects in the
    proteasome components (LMP2, LMP9 or MECL-1, etc). (8) Defects in the peptide
    transport or ER peptide loading complex (TAP1/TAP2, ERp57, calnexin, calreticulin).
    (9) Downregulation of light chain β2M can lead to complete absence of HLA-I. (10)
    Microenvironmental conditions such as glucose deprivation, hypoxia, acidosis or
    excessive IL-10, TGF-β levels can also drive loss of HLA. β2M, β−2-microglobulin;
    ER, endoplasmic reticulum; HLA, human leucocyte antigen; IFNAR1, interferon alpha
    and beta receptor 1; IL-10, interleukin 10; ISRE, interferon stimulated response
    element; TAP1, transporter associated with antigen processing 1; TGF-β, transforming
    growth factor-β.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Ifnar1
  - Ifna
  - Ifnb1
  - Stat2
  - Irf9
  - Ifnar2
  - Gast
  - Gnas
  - Ifngr1
  - Ifngr2
  - Irf1
  - B2m
  - Tap1
  - Nxf1
  - Uso1
  - Sec14l2
  - Sec14l4
  - Ly6a
  - Pdlim7
  - Pdlim5
  - Pik3r1
  - Pdk1
  - Pdpk1
  - Akt1
  - Egfr
  - Erbb2
  - Tgfbr1
  - ras
  - Hras
  - Kras
  - Rem1
  - Zhx2
  - Mdk
  - Ephb2
  - Mapk1
  - IFNAR1
  - IFNB1
  - STAT2
  - IRF9
  - IFNAR2
  - IFNGR1
  - IFNGR2
  - IRF1
  - B2M
  - PDK1
  - EGFR
  - ERBB2
  - TGFBR1
  - STAT1
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - IFNA1
  - GAST
  - GALNS
  - PAGR1
  - FLNB
  - USO1
  - NXF1
  - SEC14L2
  - TAP1
  - TAP2
  - ABCB9
  - PDLIM5
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PDPK1
  - AKT1
  - AKT2
  - AKT3
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - NR1H2
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - hop
  - bsk
  - gas
  - Galphas
  - gd
  - tap
  - P32
  - tapas
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Ras64B
  - Ras85D
  - Raf
  - Dsor1
  - Mtk
  - Erk7
  - rl
---
